Glucagon-Like Peptide-1 Receptor Agonists: A New Era in Cardiometabolic and Cardiovascular Care
Abstract
Introduction : Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have evolved from glucose-lowering medications for diabetes into foundational cardiometabolic therapies, supported by robust evidence of cardiovascular protection from major clinical trials.1 Their dual capacity to reduce hyperglycemia and promote substantial weight loss is particularly relevant in regions like Iran and the Middle East, where the prevalence of obesity (∼25%), overweight (∼60%), and diabetes (∼10%) is rising rapidly; regional diabetes prevalence is projected to increase by more than 80% by 2050.
By enhancing glucose-dependent insulin secretion, suppressing glucagon release and appetite, lowering blood pressure, improving lipid profiles, and exerting anti-inflammatory vascular effects, GLP-1 RAs such as liraglutide, semaglutide, and dulaglutide offer a comprehensive strategy for mitigating the intertwined risks of metabolic and cardiovascular disease.
2. Tajdini M, Behnoush AH, Pashang M, et al. Heart surgery over two decades: what we have learned about results and changing risks. BMC Cardiovasc Disord. 2024;24:195. doi:10.1186/s12872-024-03860-9.
3. Tariq S, Ali MA, Hassan Iftikhar HM, Fareh Ali M, Shah SQA, Perveen F, Zaman T. Long-term cardiovascular outcomes of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes: a systematic review. Cureus. 2024 Nov 14;16(11):e73705. doi:10.7759/cureus.73705.
4. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22.
5. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376(9):891-902.
6. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30.
7. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-86.
8. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-32. doi:10.1056/NEJMoa2307563.
9. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023 Sep 21;389(12):1069-84. doi:10.1056/NEJMoa2306963. PMID:37622681.
10. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-37.
11. Selvaganesan P, Karnib M, Reddy YNV, et al. TRANSFORM-AF: targeting metabolic therapy with GLP-1 receptor agonism for secondary prevention in atrial fibrillation. Heart Rhythm. 2025;22(Suppl 4):S495066-04. Presented at: Heart Rhythm Society Annual Scientific Sessions; April 24-27, 2025; San Diego, CA.
| Files | ||
| Issue | Vol 20 No 3 (2025) | |
| Section | Editorial | |
| DOI | https://doi.org/10.18502/jthc.v20i3.20107 | |
| Keywords | ||
| GLP-1 receptor agonists Cardiometabolic disease Cardiovascular outcomes | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
